Authors
Latest:
The Pandemic's Multilevel Effect on Patient AccessCoronavirus disease 2019 altered the workflow in all areas of the health care and life sciences industries, and the FDA was not exempt from pandemic-induced upheaval.
Latest:
AmerisourceBergen Rep Previews the Year Ahead for Biosimilars: What’s Coming Down the Pipeline in 2022?Sean McGowan, senior director of Biosimilars for AmerisourceBergen, forecasts potential biosimilar approvals and launches in 2022 as well as offers insights into how emerging biosimilars will impact the market and pricing in the coming years during an interview.
Latest:
Understanding the Risks, Opportunities, and Prospects of Biosimilars in 2020 and BeyondHurdles to a vibrant biosimilar market are not as insurmountable as they appear.
Latest:
FDA Approves Biocon Biologics' Bevacizumab BiosimilarBiocon Biologics expands its oncology biosimilar roster after gaining FDA approval for Jobevne (bevacizumab-nwgd), the sixth biosimilar referencing Avastin (bevacizumab).
Latest:
New Rule: Transition to BLA Pathway Is CompleteAs of today, the FDA has completed a 10-year process to bring a wider set of biologics under the biologics license pathway for approval.
Latest:
Drug Couponing: Better or Worse for Biosimilars?Payers will have to carefully mull limited options.
Latest:
COVID-19's Multifaceted Effect on BiosimilarsThe coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.
Latest:
Another European Study Finds SB4 Tolerated by Most PatientsThe study follows others that have found that SB4 works well for the majority of patients who switched from the originator etanercept, Enbrel.
Latest:
Lupin Partners With Mylan on Etanercept BiosimilarLupin recently announced that it has entered into a partnership agreement with Mylan to commercialize its proposed etanercept (Enbrel) biosimilar.
Latest:
COVID-19's Multifaceted Effect on BiosimilarsThe coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.
Latest:
Dr Andre Harvin Answers How Oncologists Can Work to Expand Access to BiosimilarsAndre Harvin, PharmD, executive director of pharmacy and oncology services at Cone Health, explains how oncologists can work with other stakeholders to expand access to biosimilars and how patients can work with providers and biosimilar manufacturers to address financial challenges.
Latest:
Using Biosimilar Filgrastim May Lead to Shorter Hospitalization, Lower Cost in PBSC MobilizationUsing the biosimilar resulted in a significantly lower drug acquisition cost, at $533.40 in the biosimilar group versus $1261.90 in the reference group.
Latest:
Federal Perspective on the Biosimilar Influence on Drug CostsProviding an overview on where the healthcare reform debate is headed, Andrew Slavitt, former head of CMS, refined the discussion to highlight the potential for biosimilars to influence the rising costs of drug products.
Latest:
Resources for Patients and Providers on Adalimumab BiosimilarsExpert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.
Latest:
PBMs Drive Up Drug Costs, Squeeze Out Generics and Biosimilars, FTC Report FindsA long-awaited report from the Federal Trade Commission (FTC) finds that vertical integration and consolidation have worked against consumers and independent pharmacies.
